Acknowledgement
The authors would like to thank Wade Martin of Emareye for his critical English revision.
References
- Ishikawa M, Hashimoto M, Kuwana N, Mori E, Miyake H, Wachi A, et al. Guidelines for management of idiopathic normal pressure hydrocephalus. Neurol Med Chir (Tokyo) 2008;48 Suppl:S1-S23. https://doi.org/10.2176/nmc.48.S1
- Relkin N, Marmarou A, Klinge P, Bergsneider M, Black PM. Diagnosing idiopathic normal-pressure hydrocephalus. Neurosurgery 2005;57:S4-S16. https://doi.org/10.1227/01.NEU.0000168185.29659.C5
- Tatsch K, Poepperl G. Nigrostriatal dopamine terminal imaging with dopamine transporter SPECT: an update. J Nucl Med 2013;54:1331-1338. https://doi.org/10.2967/jnumed.112.105379
- Mori E, Ishikawa M, Kato T, Kazui H, Miyake H, Miyajima M, et al. Guidelines for management of idiopathic normal pressure hydrocephalus: second edition. Neurol Med Chir (Tokyo) 2012;52:775-809. https://doi.org/10.2176/nmc.52.775
- Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015;30:1591-1601. https://doi.org/10.1002/mds.26424
- Molde K, Soderstrom L, Laurell K. Parkinsonian symptoms in normal pressure hydrocephalus: a population-based study. J Neurol 2017;264:2141-2148. https://doi.org/10.1007/s00415-017-8598-5
- Lee JY, Park SB, Lee M, Ju H, Im K, Kwon KY. Detailed visual assessment of striatal dopaminergic depletion in patients with idiopathic normal pressure hydrocephalus: unremarkable or not? BMC Neurol 2020;20:277.